drugset / Trial / NCT00403325
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
Phase 1
Completed
9 enrolled
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
Timeline
- Start
- 2006-08
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |